Welcome to our dedicated page for The LGL Group news (Ticker: $LGL), a resource for investors and traders seeking the latest updates and insights on The LGL Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect The LGL Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of The LGL Group's position in the market.
The LGL Group (NYSE American: LGL) released its financial results for Q1 2024, ending March 31, 2024. During this period, total revenues fell by $96,000 to $888,000 compared to Q1 2023. Income from continuing operations before taxes decreased by $193,000 to $57,000. Net income per diluted share dropped by $0.03 to $0.00. Cash and marketable securities stood at $40.89 million.
Tim Foufas, Co-CEO, noted a revenue decline in the Electronics Instruments segment but pointed out an improved order backlog. The order backlog rose to $341,000, an increase of $198,000 from December 31, 2023.
Gross margin fell to 48.0% from 56.5% in Q1 2023, attributed to a lower margin product mix and higher labor costs. Working capital was $41.17 million, and investments in U.S. Treasury money market funds provided higher net investment income.